Regulation of CYP3A4 and CYP3A5 expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor

被引:21
|
作者
Maguire, Orla [1 ]
Pollock, Catherine [1 ]
Martin, Philip [2 ]
Owen, Andrew [2 ]
Smyth, Thomas [1 ]
Doherty, Declan [1 ]
Campbell, Moray J. [3 ]
McClean, Stephen [1 ]
Thompson, Paul [1 ]
机构
[1] Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland
[2] Univ Liverpool, Dept Pharmacol, Liverpool L69 3GF, Merseyside, England
[3] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
基金
英国生物技术与生命科学研究理事会;
关键词
Vitamin D receptor; Prostate; Metabolism; CYP3A4; CYP3A5; HUMAN LIVER-MICROSOMES; PREGNANE-X-RECEPTOR; CYTOCHROME-P450; 3A4; CANCER CELLS; RADICAL PROSTATECTOMY; CLINICAL PRESENTATION; PROTEASE INHIBITOR; GENE POLYMORPHISMS; IN-VITRO; RISK;
D O I
10.1016/j.mce.2012.08.007
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We investigated the capacity for vitamin D receptor (VDR) to modulate the expression of CYP3A4 and other genes that may facilitate the oxidative inactivation of androgens such as testosterone and androstanediol within prostate cells. We report that exposure to the active hormonal form of vitamin D markedly increased gene expression of CYP3A4 and CYP3A5 and ultimately achieved levels of intracellular CYP3A enzyme activity within LNCaP prostate cancer cells that were comparable to that observed for Caco2 cells, an established model of CYP3A induction, and resulted in the increased turnover of testosterone to its inactive 6 beta-OH metabolite. We demonstrate that VDR directs CYP3A4 and CYP3A5 expression through binding to distinct regulatory motifs located within the 5' promoter regions of both genes. The current data highlight the potential application of VDR-based treatment regimes as a means to limit the bioavailability of growth-promoting androgens within the tumor microenvironment. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:54 / 64
页数:11
相关论文
共 50 条
  • [41] Variability in heteroactivation of carbamazepine metabolism by endogenous steroids: Comparison of CYP3A4 and CYP3A5 response
    Henshall, Jamie
    Galetin, Aleksandra
    Harrison, Anthony
    Houston, J. Brian
    DRUG METABOLISM REVIEWS, 2006, 38 : 110 - 111
  • [42] Variability in heteroactivation of carbamazepine metabolism by endogenous steroids: Comparison of CYP3A4 and CYP3A5 response
    Henshall, Jamie
    Galetin, Aleksandra
    Harrison, Anthony
    Houston, J. Brian
    DRUG METABOLISM REVIEWS, 2006, 38 : 6 - 6
  • [43] CYP3A4 and CYP3A5 Expression is Regulated by CYP3A4*1G in CRISPR/Cas9-Edited HepG2 Cells
    Yang, Weihong
    Zhao, Huan
    Dou, Yaojie
    Wang, Pei
    Chang, Qi
    Qiao, Xiaomeng
    Wang, Xiaofei
    Xu, Chen
    Zhang, Zhe
    Zhang, Lirong
    DRUG METABOLISM AND DISPOSITION, 2023, 51 (04) : 492 - 498
  • [44] Genetic Variants of CYP3A4 and CYP3A5 in Cynomolgus and Rhesus Macaques
    Uno, Yasuhiro
    Matsushita, Akinori
    Osada, Naoki
    Uehara, Shotaro
    Kohara, Sakae
    Nagata, Ryoichi
    Fukuzaki, Koichiro
    Utoh, Masahiro
    Murayama, Norie
    Yamazaki, Hiroshi
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (02) : 209 - 214
  • [45] Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5
    Soars, M. G.
    Grime, K.
    Riley, R. J.
    XENOBIOTICA, 2006, 36 (04) : 287 - 299
  • [46] Influence of both receptor and donor's CYP3A5 and CYP3A4 genotype in tacrolimus metabolism in liver transplant patients
    Prieto, J. L. Rubio
    Macher, H. C.
    Gomez-Bravo, M. A.
    De Veas-Silva, J. L. Garcia
    Suarez-Artacho, G.
    Rodriguez-Rodriguez, A.
    Sanchez-Pozo, C.
    Guerrero-Montavez, J. M.
    Rubio-Calvo, A.
    CLINICA CHIMICA ACTA, 2024, 558
  • [47] The evaluation of CYP3A4 and CYP3A5 genetic profiles in Turkish population
    Arici, Merve
    Ozhan, Gul
    ISTANBUL JOURNAL OF PHARMACY, 2016, 46 (01): : 15 - 22
  • [48] Pharmacogenetics of Carbamazepine: A Systematic Review on CYP3A4 and CYP3A5 Polymorphisms
    Riffi, Rachda
    Boughrara, Wefa
    Chentouf, Amina
    Ilias, Wassila
    Brahim, Narimene Malika Taieb
    Berrebbah, Amel Alioua
    Belhoucine, Fatma
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2024, 23 (12) : 1463 - 1473
  • [49] Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population
    Mutawi, Thuraya M.
    Zedan, Mohamed M.
    Yahya, Raida S.
    Zakria, Mahmoud M.
    El-Sawi, Mamdouh R.
    Gaedigk, Andrea
    PHARMACOGENOMICS, 2021, 22 (06) : 323 - 334
  • [50] Discovery of a Highly Selective CYP3A4 Inhibitor Suitable for Reaction Phenotyping Studies and Differentiation of CYP3A4 and CYP3A5
    Li, Xiaohai
    Song, Xinyi
    Kamenecka, Theodore M.
    Cameron, Michael D.
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (09) : 1803 - 1809